CEBPA and acute myeloid leukemia: As a result, overall survival over 5 years is only about 27%.2 There are molecular markers and genetic mutations that have been identified in the genomes of AML patients and cytogenetic data indicates that they are: Runx1, Flt3-ITD, MLL-PTD, NPM1, CEBPA, and ASXL1.3 There are about 25% of cases of AML that have mutations in the Flt3 (FMS-like tyrosine kinase-3 receptor) gene.